通过导入人乳头瘤病毒16型E6/E7基因和人端粒酶逆转录酶建立永生化人肝细胞作为基于肝细胞治疗的细胞来源。
Establishment of immortalized human hepatocytes by introduction of HPV16 E6/E7 and hTERT as cell sources for liver cell-based therapy.
作者信息
Tsuruga Yosuke, Kiyono Tohru, Matsushita Michiaki, Takahashi Tohru, Kasai Hironori, Matsumoto Shuichiro, Todo Satoru
机构信息
Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo 060-8648, Japan.
出版信息
Cell Transplant. 2008;17(9):1083-94.
For future cell-based therapies for liver diseases, the shortage of cell sources must be resolved. Immortalized human hepatocytes are expected to be among the new sources. In addition to telomerase activation by the introduction of human telomerase reverse transcriptase (hTERT), inactivation of the p16/RB pathway and/ or p53 by E6/E7 of human papillomavirus type 16 (HPV16) has been shown to be useful for efficient immortalization of several human cell types. Here we report the immortalization of human hepatocytes by the introduction of HPV16 E6/E7 and hTERT. Human adult hepatocytes were lentivirally transduced with HPV16 E6/E7 and hTERT. Two human immortalized hepatocyte cell lines were established and were named HHE6E7T-1 and HHE6E7T-2. Those cells proliferated in culture beyond 200 population doublings (PDs). Albumin synthesis and expression of liver-enriched genes were confirmed, but gradually decreased as passages progressed. Karyotype analysis showed that HHE6E7T-1 cells remained near diploid but that HHE6E7T-2 cells showed severe aneuploidy at 150 PDs. Subcutaneous injection of these cells into severe combined immunodeficiency (SCID) mice did not induce tumor development. Intrasplenic transplantation of dedifferentiated HHE6E7T-1 cells over 200 PDs significantly improved the survival of acetaminophen-induced acute liver failure SCID mice. In conclusion, we successfully established immortalized human hepatocytes that retain the characteristics of differentiated hepatocytes. We also showed the reduction of hepatocyte-specific functions in long-term culture. However, the results of intrasplenic transplantation to SCID mice with acetaminophen-induced acute liver failure showed the possibility of HHE6E7T-1 serving as a cell source for hepatocyte transplantation.
对于未来基于细胞的肝脏疾病治疗方法而言,必须解决细胞来源短缺的问题。永生化人肝细胞有望成为新的细胞来源之一。除了通过引入人端粒酶逆转录酶(hTERT)激活端粒酶外,人乳头瘤病毒16型(HPV16)的E6/E7使p16/RB通路和/或p53失活已被证明对几种人类细胞类型的高效永生化有用。在此,我们报告通过引入HPV16 E6/E7和hTERT使人肝细胞永生化。用HPV16 E6/E7和hTERT对成人肝细胞进行慢病毒转导。建立了两个人永生化肝细胞系,分别命名为HHE6E7T-1和HHE6E7T-2。这些细胞在培养中增殖超过200个群体倍增(PDs)。白蛋白合成和肝脏富集基因的表达得到证实,但随着传代进行逐渐下降。核型分析表明,HHE6E7T-1细胞仍接近二倍体,但HHE6E7T-2细胞在150个PDs时显示出严重的非整倍体。将这些细胞皮下注射到严重联合免疫缺陷(SCID)小鼠中未诱导肿瘤发生。将超过200个PDs的去分化HHE6E7T-1细胞脾内移植可显著提高对乙酰氨基酚诱导的急性肝衰竭SCID小鼠的存活率。总之,我们成功建立了保留分化肝细胞特征的永生化人肝细胞。我们还显示了长期培养中肝细胞特异性功能的降低。然而,对乙酰氨基酚诱导的急性肝衰竭SCID小鼠进行脾内移植的结果表明,HHE6E7T-1有作为肝细胞移植细胞来源的可能性。